DEVELOPMENT OF THE VERTEBRATE heart begins when a sheet of mesoderm specified for cardiac development forms a crescent that folds toward the ventral midline to create a linear tube. At the eighth day of embryogenesis in the mouse, the distinction between ventricular and atrial myocardium is first recognized. At this time the linear heart begins to function as a pump. The atria remain thin-walled, receiving venous return at low pressure; while the ventricles begin to thicken by both hyperplasia and hypertrophy, pumping blood against a higher afterload (3).
Anatomists have previously defined structural and ultrastructural differences between the upper and lower chambers of the heart. The Golgi apparatus and associated atrial granules are more prominent components in atrial myocytes. The sarcoplasmic reticulum in atrial cells is more complex and robust, whereas the transverse-axial tubular system is poorly developed compared with its ventricular counterpart (10) . A distinct endocrine role has been long recognized for the atria. The thin, easily distensible wall, thick endocardium, and abundant granules containing ANP allow the atria to both monitor and modify intravascular volume. Finally, and most obviously, the pressure in the atria normally only rises to about 10 mmHg while ranging from 10 to 120, or higher, in the ventricle. This produces (and requires) a large difference in the proportion of cellular proteins and energy utilization devoted to contraction.
Some of the regional variation in gene expression that underlies these functional differences is known. There are a handful of relatively highly expressed and well-characterized genes for which transcriptional differences have been recognized and even functional effects described (reviewed in Refs. 11 and 16) . For example, substitution of ventricular for atrial myosin light chain isoforms is sufficient to confer ventricularlike calcium sensitivity and cross-bridge cycling characteristics on atrial cardiomyocytes (27) . Differences in depolarization and contractility between the atria and ventricles have been ascribed to differential regulation of several genes including angiotensin II receptor subtypes (31) , sarcoplasmic reticulum calcium ATPase (24) , potassium channel related genes (4, 7, 32) , and phospholamban (2, 19) .
To more comprehensively evaluate the molecular basis for the differences between the atria and ventricles, we used a deeply representative, cardiac-specific, cDNA microarray to compare the transcription profiles between atria and ventricles and identify those transcripts that are differentially expressed between the two tissues. We then examined these differentially regulated genes for transcription factor binding motifs within evolutionarily conserved noncoding regions that could confer chamber-specific regulation of expression. Finally, we demonstrated the greater atrial abundance and transcriptional activity of one of these transcription factors identified as a candidate for contributing to Article published online before print. See web site for date of publication (http://physiolgenomics.physiology.org).differential gene expression between the atria and ventricles.
MATERIALS AND METHODS
Microarray creation. Libraries were created from cardiac and skeletal muscle RNA obtained from young adult mouse tissues (male and female). mRNA was prepared with TRIzol reagent (Invitrogen, Carlsbad, CA) and oligo-dT resin (Qiagen, Valencia, CA) according to the manufacturer's protocols. Two micrograms of mRNA was converted to cDNA and subcloned into pAMP10 (Invitrogen, Carlsbad, CA). Eight-thousand clones of each library were picked and grown on highdensity filters. Insert was prepared from 30 of these clones, batch labeled by random priming with [ 32 P]dCTP, and used to probe the library. Hybridizing clones were removed from subsequent consideration, and the process was repeated until each clone in the probe was only recognizing an average of 1.2 of the remaining clones (10 iterations). Remaining clones were sequenced by dideoxy chain termination ("Big Dye" chemistry and 377 apparatus; PerkinElmer, Boston, MA) and mapped back to Unigene consensus sequences. A total of 1,706 independent clones were identified in the cardiac library and 3,982 in the skeletal muscle. Also, two previously characterized IMAGE consortium libraries (20) were purchased (Soares, Image ID 397; Stratagene, Image ID 290; Incyte Genomics, Palo Alto, CA). The available sequence information was confirmed in a sample of 96 clones from each library. Accession numbers were used to obtain Unigene identifications with Arrogant gene collection management software (available at http://lethargy.swmed.edu). The "refseq" identification was used to parse unique sequences from the library clones. Our criteria for nonredundancy were fulfilled by 3,704 clones from the fetal cardiac library and 2,306 clones from the adult cardiac library. We did not remove interlibrary redundancy, both to maintain duplicate clones on the array and to prevent removal of library-specific isoforms. In total, 7,716 heart clones were applied to the array. In silico comparisons show that ϳ5,000 independent cardiac genes are represented in this collection. Details of library construction and all target clones can be found at http://pga.swmed.edu. Plasmid DNA was isolated from these clones and inserts were amplified with M13 primers. After ethanol precipitation, these inserts were resolvated in 7% DMSO and spotted onto poly-lysine-coated microscope slides. These slides were postprocessed with UV cross-linking and succinic anhydride blocking as previously described (6) .
RNA extraction, hybridization, and quantification. Hearts were harvested from 6-to 8-wk-old male C57BL/6 mice, and the atria and ventricles were carefully separated under a dissecting microscope. Total RNA was isolated with TRIzol reagent according to the manufacturer's protocol. Probes were prepared from 20 g of pooled total RNA by reverse transcription primed with oligo-dT (Superscript II, GIBCO-BRL) incorporating Cy3 or Cy5. The labeled probes were combined, concentrated on a 30 kDa size-exclusion filter (Amicon) and brought to a final volume of 50 l of 3ϫ SSC/0.3% SDS containing 10 g of poly-A RNA and 10 g of mouse CotI DNA. Hybridization was carried out in a slide chamber in 62°C water bath overnight. Slides were washed to a final stringency of 0.1ϫ SSC at room temperature. They were read in a GenePix scanner at photomultiplier tube settings that produced equivalent signal in both channels and low background. Data were imported into an automated spreadsheet where a background threshold, based on several hundred blank solvent spots scattered through the array, was determined for each hybridization and mean log ratio normalization was performed (8) [the Marc-V program (28) is available for download at http://pga.swmed.edu]. Highly regulated genes were resequenced to confirm identity and obtain more complete sequence information on expressed sequence tags (ESTs).
Array results were confirmed by real-time PCR assays. We designed oligonucleotide primers from the cDNA sequence that were predicted to cross an intron (see Table 2 ); if the mouse gene organization was not available, then we used homology to the human gene. All amplicons were initially resolved on a 2% agarose gel to confirm that only a single product was generated. These primers were used to amplify product from cDNA representing 5 ng of total RNA. PCR was run in triplicate with SYBR green fluorophore (Molecular Probes, Portland, OR) in a Opticon device (MJ Research, Waltham, MA). Expression level was interpolated from a standard curve generated from a series of dilutions at cycle times where threshold intensity was clearly exceeded. Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control. A standard two-phase reaction (95°C for 15 s, 60°C for 1 min) worked for all amplifications.
Animal manipulations. Generation of the myocyte enhancer factor-2 (MEF2) activity indicator mouse was reported previously (25) . Male, 6-to 8-wk-old transgenic mice were treated with isoproterenol (15 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 for 7 days) (30), angiotensin II (200 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 for 7 days) (15), or saline by osmotic minipump (Alzet, model 1007D), implanted during Avertin anesthesia. Hyperthyroidism was obtained by daily intraperitoneal injection (triiodothyronine, 1 g ⅐ g Ϫ1 ⅐ day Ϫ1 for 7 days) (17) . Histology. Mouse hearts were embedded in tissue freezing medium (Triangle Biomedical Sciences, Durham, NC), and 5-m sections were obtained in a four-chamber plane with a cryostat. These sections were incubated first with antibody to the carboxy terminus of MEF2 (sc-313, Santa Cruz Biotechnology), and binding was revealed with FITC-labeled secondary antibody (Fisher Scientific, Pittsburgh, PA). Counterstaining with propidium iodide indicated the location of nuclei. Subcellular localization of MEF2 signal was obtained with "nearest-neighbor" deconvolution software (OpenLab version 2, Improvision) on a Zeiss Axiovert 100M model inverted microscope. For detection of ␤-galactosidase, hearts were briefly fixed in 2% paraformaldehyde/0.2% glutaraldehyde in PBS on ice for 90 min followed by incubation in X-gal staining solution [5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 2 mM MgCl2, 1 mg/ml 5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside (X-gal) in dimethylformamide] at room temperature overnight. In addition, from a subset of animals in each group, 200-m sections were obtained with a Vibratome (Energy Beam Sciences, Agawam, MA) and stained with X-gal substrate in a similar manner.
In situ hybridization was performed to identify the location of gene expression as previously described (29) . Briefly, riboprobes were generated, from the plasmids used to create the array targets, using T7 or Sp6 RNA polymerase (Maxiscript; Ambion, Austin, TX) according to the manufacturer's recommendations. They were applied over deparaffinized heart sections that had been briefly microwaved and Pronase E-treated to help unmask RNA. Hybridization was conducted for 14 h at 55°C in 50% formamide, 0.3% dextran, 1ϫ Denhardt's solution, 0.5 mg/ml tRNA, and 7.5 ϫ 10 5 cpm of the probe. The slides were then washed to a final stringency of 65°C in 50% formamide/2ϫ SSC for 30 min. K.5 nuclear emulsion (Ilford Imaging, Paramus, NJ) was applied to the slides, which were then exposed at 4°C for 14 days.
Immunoblotting. Atria and ventricles were homogenized in RIPA buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, pH 7.4) supplemented with 1% Nonidet P-40, PMSF (0.2 M), leupeptin (10 g/ml), and pepstatin (10 g/ml). The lysate was cleared by centrifugation, and 10 g of protein (determined with Bradford reagent; Bio-Rad Laboratories, Hercules, CA) was subjected to electrophoresis in a 10% SDS polyacrylamide gel and transferred onto PVDF membranes. The blots were incubated with a 1:2,000 dilution of the same anti-MEF2 antibody used for immunohistology, followed by HRP-labeled secondary antibody (Fisher Scientific, Pittsburgh, PA). The signals were detected by SuperSignal chemiluminescent reagent (Pierce Endogen, Rockford, IL).
Bioinformatic analyses. Mouse and human gene sequences were extracted from either National Center for Biotechnology Information (NCBI) or Celera databases. We were able to obtain adequate sequence data from both species to analyze 17 of the atrial-expressed genes and 6 of the ventricularexpressed genes. We added a further 29 genes with a ventricle-to-atrial expression ratio of between 1 and 3 amenable to this analysis. We used rVISTA software (22) to identify predicted transcription factor binding sites within 5 kb upstream and downstream of the gene. The default parameters used with this program included a TRANSFAC search with core similarity 0.75, matrix similarity 0.8, and evolutionary conservation (80% similarity) of the neighboring 24-bp window of sequence. We have included a predicted MEF2 site in a non-atrial-specific gene (myomesin 1) even though it was not within a long evolutionarily conserved noncoding sequences (NCS), simply because the rVISTA software, using a moving window of similarity, detected a match. If we had not included this gene in our analysis, then the statistical significance of our findings would be even more impressive.
Statistics. Expression data for each of the results shown (Table 1) were generated from the average of four independent determinations obtained from the hybridization target on the array. We calculated confidence intervals from the standard deviation of these averaged expression ratios using a standard t-test (shown as a range for fold change). Pearson correlation was used to compare the overall similarity of the hybridization result from entire arrays. A Fisher exact test was used to check the significance of differences in abundance of predicted transcription factor binding sites between groups of genes.
RESULTS
We used a tissue-specific cDNA microarray to compare RNA samples from pooled atria and ventricles. Two sets of dye-reversal cDNA microarrays (four arrays) comparing atria and ventricles were used to calibrate each gene. The results of the hybridizations were highly similar. Pearson correlation for all results on the array was 0.78 when atrial RNA was labeled with Cy3 and 0.82 when atrial RNA was labeled with Cy5. Fluorescence intensities of 670 target spots had Ͼ1.8 fold differential expression in either direction in any hybridization. The four results were averaged for each of these clones. After confirmation and resolution of redundancy, 9 genes were more than 3-fold more abundant in ventricle, and 20 genes were more than 3-fold more abundant in atrium. Of these 29 substantially differentially regulated genes, 19 were known genes and 10 were similar only to otherwise uncharac- Data presented are specific to the clone with the accession number provided. The number of clones on the array that showed similar regulation is provided in parentheses after the gene name. Fold regulation is shown with 95% confidence intervals in parentheses. * Unigene cluster has been substituted when accession number was indeterminate after resequencing. † EST denoted as novel has no homology to any other gene or EST in the public databases.
terized ESTs. One of the anonymous ESTs was entirely novel, with no homolog in any database. Results and 95% confidence intervals were determined for the fold change of each of these genes and are shown in Table 1 . Among the most differentially expressed genes were the expected atrial-specific transcripts for atrial natriuretic factor (ANF) and the atrial and ventricular isoforms of myosin light chain. We confirmed differential expression of 12 of these genes by real-time PCR. The results show excellent correlation of array and PCR results (Fig. 1) .
The expression pattern of several genes of particular interest was defined by in situ hybridization (Fig. 2) . The atrial isoform of myosin light chain gave the expected intense atrial-specific signal localized over myocytes. Other probes showed atrial-specific expression concentrated in myocytes, vascular endothelium, parietal pericardium, or other cellular components. Not all Fig. 2 . In situ hybridization of atrial-specific transcripts. The left column shows 4 chamber sections of adult mouse heart with in situ hybridization of EST vv36h12 (A-C), myosin light chain 1A (D-F), gelsolin (G-I), or glutathione peroxidase 3 (J-L). The middle column shows higher magnification views that localize signal to the atrial myocytes (B and E), the fibroblasts (H), or the myocytes and pericardiac fat (K). The right column shows bright-field images of the same sections that allows this more precise histological evaluation (bar in L ϭ 100 m). RA and LA, right and left atrium, respectively; RV and LV, right and left ventricle, respectively. gave signal greater than background; those that did confirmed the direction of expression in 9 of 10 genes.
To search for cis-acting regulatory sequences in atrial and ventricular highly regulated genes, we used rVISTA ("regulatory visualization tool for alignment," http://pga.lbl.gov/rvista.html) to compare the mouse and human sequences of the genes. This software looks at evolutionarily conserved transcription binding factor sites, includes a flexible criterion for alignment within noncoding sequences, and appears to reduce false-positive predictions of binding sites. The result of this analysis showed 4 of the 17 atrial-expressed genes to have conserved MEF2 sites, whereas only one of 35 ventricular-predominant genes had a conserved site (P exact ϭ 0.05, Table 3 ).
The array contained cDNAs for the four isoforms of MEF2 (1). Hybridization signal was low for these cardiac transcription factors, close to the overall threshold used for the general analysis of the array data. Nonetheless, those targets that gave signal greater than background suggested that MEF2 isoforms might be more abundant in atria than ventricles, with ratios of atrial to ventricular expression of 1.4, 1.2, 1.2, and 1.3 for MEF2A, -2B, -2C, and -2D, respectively. We then examined expression levels of MEF2 by real-time PCR with oligonucleotides that distinguished the various isoforms. This established that MEF2A, -2B, -2C, and -2D were 2.1, 1.5, 2.7, and 2.0-fold higher in atria than ventricles, respectively. By Western blotting we found that MEF2 proteins are more abundant in atria than in ventricles (Fig. 3E) . The antibody used recognizes MEF2A, -2C, and -2D, and the principal band seen on the Western blot has an implied molecular weight most consistent with MEF2A (18) . Immunohistochemistry confirmed that MEF2 protein is located in myocytes with more intense signal in atria than in ventricles. Higher resolution images obtained with deconvolution software show that the MEF2 is found predominantly in discreet sublaminar regions of the nucleus (Fig. 3D) .
To assess the functional role of elevated levels of MEF2 in the atria we used a "MEF2 indicator animal" that has a transgene with concatamerized MEF2 binding sites (taken from the desmin gene) upstream of a ␤-galactosidase reporter construct (25) . At baseline there was little ␤-galactosidase activity in either the atrium or ventricle. After stimulation with the hypertrophic agents isoproterenol, angiotensin II, and thyroid hormone, ␤-galactosidase activity was detected ANF  AGAAACCAGAGAGTGGCAGAG  CAAGACGAGGAAGAAGCCCAG  AA530365  GTTTGTTACCCAAACATAGGGCC  CACAACATGTGGTAGAGGCACC  AA789894  TCCCGTACTCCTCATCATCACC  AATTTGTTGAATCTGCAGGACTAGG  Abcd4  CCTTGAGAAGTTCACTCCTGGG  TCCGCTGCTCAGATGAACC  Atp5c1  CTGCAAAGTATGCCCGGG  CCTCAGGTGCCTTAATATCAGCC  Bak1  TCATCGGAGATGATATTAACCGG  GCTGATGCCACTCTTAAATAGGC  BNP  CCAGTCTCCAGAGCAATTCAAGAT  GCTAATTCACAAAGGACTCGAGGT  Clusterin  GTCTCCACCGTGACCACCC  CTGGTAACACCACTGTGATGGG  CTGF  CCGAGAAGGGTCAAGCTGC  TGTGTCTTCCAGTCGGTAGGC  Debt91  CAGCGTTATCCAATGGTTACTGGC  CCTGGGTTCCACTGCAGAGC  Dkk3  AGAGGAGCCATGAATGTATCATTG  TCGGGTGCATAGCATCTGC  FHL2  AAGGAGAATCAGAACTTCTGCGTG  CGGTAAGTAACACCTCCTGTGGT  GAPDH  TGCACCACCAACTGCTTAG  GGATGCAGGGAT GATGTTC  Gelsolin  CAGACAGCTCCTGCCAGTATCC  GAGTTCAGAGCACCAGACTTAGGC  GPX3  TACTCCCCAGTCTCAAGTATGTTCGACC  TTCTGCAGTGGGAGGGCAGG  MEF2A  AAGTACCGGCAGTGCAAGTGG  CCCTTGAGTTTACAAATCCATTCC  MEF2B  AACGCCTCTTCCAGTATGCG  CTCCTCTTAAGTGTCTGAAGGATATCC  MEF2C  GATGCCATCAGTGAATCAAAGG  GTTGAAATGGCTGATGGATATCC and was substantially greater in the atria than in the ventricles (Fig. 4) . We did not detect any increase in MEF2 protein by Western blotting with these stimuli (data not shown), suggesting that the increase in activity may be due to posttranslational activation of MEF2, as has been previously demonstrated (12, 23) . We confirmed that the greater staining seen in the atria was not a technical artifact of access to substrate by repeating the ␤-galactosidase assay on fresh Vibratome sections of heart (data not shown). We then explored whether the increased MEF2 activity observed with isoproterenol stimulation was reflected in regulation of putative target genes in the atrium. We examined four categories of genes: atrialpredominant genes with 1) at least one MEF2 site in an evolutionarily conserved sequence, 2) at least one MEF2 site with evolutionary alignment (but outside of a highly conserved region), 3) no MEF2 site recognized by the rVISTA software, and 4) genes without chamber specificity or ventricular predominance (and no aligned or conserved MEF2 sites). As shown in Table 4 , seven of the 14 atrial-predominant genes showed Ͼ1.8-fold upregulation in the atria of isoproterenol-treated mice, and only one of the 7 genes examined with neutral or ventricular predominance was upregulated. However, among atrial-predominant genes, three of the six genes lacking evolutionarily conserved MEF2 sites showed such upregulation.
DISCUSSION
This study illustrates the power of a tissue-specific microarray to identify genes that are expressed in specific regions of the heart. The array data revealed 29 Ͼ3-fold differentially expressed genes including several of those previously shown to have differential expression in the atria and ventricles. Twenty of them are more abundant in atria, and nine are more highly expressed in ventricles. Many are novel or uncharacterized ESTs of unknown function. Some of the known genes may contribute to a physiological distinction between atria and ventricle. For example, the message for a homolog of sarcolipin is abundant in atria, whereas that of the related protein phospholamban is more abundant in ventricle. In fast skeletal muscle, sarcolipin regulates SERCA1, whereas phospholamban regulates SERCA2A in the heart (5). The abundance of the mRNA for the sarcolipin homolog in the atria, and the relative paucity of phospholamban, raises the intriguing possibility that this protein may play a role in regulating calcium pools in the atria, perhaps contributing to the distinct contractile attributes of atrial tissue (24) . As the roles of genes that are regulated in a chamber-specific fashion is elucidated, they will provide further clues to the functional and structural differences between atria and ventricles.
Even for rare transcripts, such as MEF2 isoforms, the array produced data that was confirmed by other methods. Members of the MEF2 family of transcription factors bind a conserved AT-rich DNA sequence that is required for appropriate expression of many cardiac structural genes. When the MEF2C gene is completely deleted, the heart tube does not undergo looping morphogenesis, and a subset of cardiac muscle genes are not expressed in embryonic heart, including ANF and MLC1A (which are found predominantly in the atrium in the adult animal) (21) . Several of these MEF2-regulated genes are also upregulated in adult atria with hypertrophic stress. This suggests that the higher MEF2 levels identified in the atria contribute to dynamic, chamber-specific, transcriptional responses in the adult heart. Distinct spatial segregation of gene expression occurs very early in cardiac development (reviewed in Ref. 3) . During later embryonic development of the heart, there is likely to be an interplay of hemodynamic stimuli and developmental programming that determines chamber-specific gene expression. At parturition there is an abrupt change in afterload and filling pressures and continued structural remodeling of the cardiac chambers (9) . Later in life, a variety of stresses can elicit transcriptional responses in the heart. These include structural remodeling that occurs with ventricular dysfunction and hypertrophy. In chronic atrial fibrillation there is a process of electrophysiological remodeling that makes the atrium resistant to defibrillation and reduces the likelihood of maintaining sinus rhythm (26) . Here we have identified a large number of genes that are differentially regulated in a chamberspecific manner. Recent studies have shown that nontranscribed regulatory sequences tend to be evolutionarily conserved and support the use of comparative genomics as an effective tool for the discovery of biologically active gene regulatory elements (13, 14, 33) . We have examined the sequence of these coordinately expressed genes to identify conserved transcription factor binding sites that might confer chamber specificity and confirmed that transcriptional activity of one of these factors is indeed higher in the atria. Interestingly, many atrial-specific genes are upregulated by the isoproterenol stimulus regardless of whether they have an identified MEF2 site in an evolutionarily conserved position. Our interpretation of these data (based on this relatively small sample of genes), is that atrial-predominant genes are more responsive to adrenergic stimulation as a class. This in turn suggests a "transcriptional field" defined by a chamber-specific mélange of transcription factors, which includes MEF2, that are enriched or more active in atrium. We think it likely that these transcription factors maintain both higher constitutive expression levels and the potential for greater responsiveness of atrial-predominant genes.
More work will be needed to establish the biological significance of evolutionarily conserved binding sites for transcription factors as well as the physiological significance of chamber-specific gene expression in the heart. The transcriptional mapping presented here provides the framework for greater refinement of therapeutic efforts utilizing gene regulation or expression. It also establishes the foundation for a more detailed understanding of normal and pathological regulation of cardiac gene expression. 
